Rifampicin — Drug Intelligence | 24 EU Trials

Filter these 24 trials by condition, phase, country and more.

Open in Search →

24 Registered trials

17 Recruiting

3 Completed trials

18 Sponsors

8 Countries

Phase III

Phase II

Phase IV

Phase III: 9 Phase II/III: 2 Phase II: 4 Phase IV: 9

Oversight events:

3 temporary halts across 2 trials

View oversight register →

Indications tested

Endocarditis enterococcal 1 Staphylococcal infection 1 Medical device site joint infection 1 Implant site infection 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Nantes 3 Assistance Publique Hopitaux De Paris 2 Centre Hospitalier Universitaire Amiens Picardie 2 Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca 2 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla 2 UZ Leuven 2 Bellvitge University Hospital 1 Centre Hospitalier De Pau 1 Friedrich-Schiller-Universitaet Jena 1 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL 1 Institut Pasteur 1 Leiden University Medical Center 1

All trials

24 total

Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in… Pending

2024-518350-17-00 Phase IV 1 country Vaestra Goetalandsregionen
A randomised, prospective phase II study of pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in a shortene… Pending

2024-518772-32-00 Phase II 1 country Region Oestergoetland
RIFAMAB : Rifabutin versus rifampicin, staphylococcal prosthetic joint infection, multicenter randomized, open-label, non-inferiority trial Pending

2024-519894-20-01 Phase III 1 country Centre Hospitalier De Tourcoing
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci Pending

2026-526149-91-00 Phase III 1 country Friedrich-Schiller-Universitaet Jena
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients Recruiting

2023-509885-39-00 Phase III 3 countries Stichting Radboud University Medical Center
Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter ran… Recruiting

2024-518018-22-00 Phase III 1 country Centre Hospitalier Universitaire De Nantes
Rapid Oral Switch in Infectious Endocarditis, the ROSIE study Recruiting

2025-524484-20-00 Phase IV 1 country UZ Leuven
The DALBA-study Introduction of the antibiotic dalbavancin in orthopaedic surgery – an evaluation of: • Health economic costs • Patient-repo… Recruiting

2025-522088-13-00 Phase IV 1 country Region Midtjylland
AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe… Recruiting

2023-506843-40-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
Clindamycin for the treatment of infections: the influence of rifampicin and obesity on PK/PD target attainment Recruiting

2024-515872-12-00 Phase IV 1 country UZ Leuven
A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradeni… Recruiting

2023-505818-16-00 Phase III 1 country Institut Pasteur
Rifampicin at High Dose for Difficult-to-Treat Tuberculosis (RIAlta) study Recruiting

2024-519983-42-00 Phase II 2 countries Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Ampicillin and ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis. Recruiting

2024-511719-40-00 Phase IV 1 country Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted a… Recruiting

2023-508442-18-00 Phase III 1 country Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
SAVE- oral antibiotics for treatment of vertebral osteomyelitis Recruiting

2023-507617-96-01 Phase IV 1 country Rigshospitalet
Impact of rifampicin in treatment outcome of Cutibacterium spp. prosthetic joint infections - RIFACute Recruiting

2022-502974-18-00 Phase II/III 1 country Centre Hospitalier Universitaire De Nice
Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting

2023-503582-35-00 Phase IV 4 countries University Medical Center Utrecht
Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterre… Recruiting

2024-514952-34-00 Phase III 1 country Assistance Publique Hopitaux De Paris
The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ… Recruiting

2022-501620-26-00 Phase IV 1 country Leiden University Medical Center
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) Recruiting

2024-512759-19-00 Phase II 1 country Assistance Publique Hopitaux De Paris
CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co… Recruiting

2024-518578-15-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
Efficacy of dalbavancin in osteoarticular infections associated with hip, knee and shoulder prostheses PRO-DALBA Ended

2024-518183-12-00 Phase II/III 1 country Centre Hospitalier Universitaire De Nice
Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease. Ended

2023-506432-32-00 Phase IV 1 country Bellvitge University Hospital; Fundacio Institut D'Investigacio Biomedica De Bel…
RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BAS… Ended

2023-509075-17-00 Phase II 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Showing 1–24 of 24 trials

← All drugs A–Z